Patent intelligence · US
US 11787800
BRD9 degraders and uses thereof
BRD9 degraders and uses thereof
Patent details — US 11787800
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 17, 2023
- Expiration
- Oct 12, 2043
- Applicant
- FOGHORN THERAPEUTICS INC.
- Claims
- 24
- CPC classes
- A61P, A61P35/00
Quick answer
US 11787800 (BRD9 degraders and uses thereof) is held by FOGHORN THERAPEUTICS INC.. Status: granted. Granted Oct 17, 2023. Expires Oct 12, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- FOGHORN THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61P, A61P35/00
More from FOGHORN THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12391686
Compounds and uses thereof
granted -
US 12383555
Methods of treating cancers
granted -
US 12383560
Compounds and uses thereof
granted -
US 12384776
Compounds and uses thereof
granted -
US 12351579
Compounds and uses thereof
granted -
US 12139487
Compounds and uses thereof
granted -
US 11851445
Compounds and uses thereof
granted
Frequently asked questions
What is US patent 11787800?
US 11787800 (BRD9 degraders and uses thereof) is held by FOGHORN THERAPEUTICS INC.. Status: granted. Granted Oct 17, 2023. Expires Oct 12, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11787800?
FOGHORN THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 11787800 expire?
Our index shows an expiration date of Oct 12, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.